author-photo

Michael Amatangelo

Bristol-Myers Squibb

8

Papers

18

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
CC-92480 Enhances Cell-Autonomous Cytotoxicity through Blockade of G 2/M Transition When Combined with Bortezomib/Dexamethasone in Pre-Clinical Multiple Myeloma

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Iberdomide-Treated Myeloma Patients

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Preclinical and Translational Support for Clinical Development of Iberdomide in Combination with Proteasome Inhibitors: Mechanism of Synergy in Clinical Trial CC-220-MM-001

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Preclinical and Translational Data Support Development of Iberdomide in Combination with CD38- and SLAMF7-Directed Monoclonal Antibodies: Evidence for Rational Combinations

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)